Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SSTR4 | P31391 | 2/20 | 0.46 |
| ▸ | CACNA1G | O43497 | 6/20 | 0.44 |
| ▸ | CACNA1H | O95180 | 6/20 | 0.44 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.44 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.44 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.44 |
| ▸ | SCN10A | Q9Y5Y9 | 1/20 | 0.44 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.42 |
| ▸ | HCRTR1 | O43613 | 7/20 | 0.42 |
| ▸ | HCRTR2 | O43614 | 7/20 | 0.42 |
| ▸ | CACNA1I | Q9P0X4 | 5/20 | 0.42 |
| ▸ | SLC13A5 | Q86YT5 | 2/20 | 0.41 |
| ▸ | GPBAR1 | Q8TDU6 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23344679 | 0.83 | SCN9A (0.41) | SSTR4CACNA1GCACNA1HKCNH2SCN5A | |
| SCHEMBL3287500 | 0.83 | SCN9A (0.42) | CACNA1GCACNA1HKCNH2SCN5ASCN2A | |
| SCHEMBL30931696 | 0.83 | SCN9A (0.42) | CACNA1GCACNA1HKCNH2SCN5ASCN2A | |
| SCHEMBL18015821 | 0.80 | MAOB (0.46) | — | |
| SCHEMBL12948866 | 0.80 | SLC13A5 (0.52) | SSTR4SCN2ASCN10ASLC13A5 | |
| SCHEMBL13424282 | 0.79 | SSTR4 (0.45) | SSTR4SCN9AHCRTR1HCRTR2GPBAR1 | |
| SCHEMBL18726968 | 0.78 | SCN9A (0.43) | SSTR4CACNA1GCACNA1HKCNH2SCN5A | |
| SCHEMBL24306108 | 0.78 | GRM5 (0.47) | SSTR4SCN9AHCRTR1HCRTR2 | |
| SCHEMBL31143575 | 0.77 | RXRA (0.44) | SSTR4KCNH2SCN5ASCN2ASCN10A | |
| SCHEMBL28080928 | 0.77 | RXRA (0.44) | SSTR4KCNH2SCN5ASCN2ASCN10A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120108595-A1 | PLATELET-ACTIVATING FACTOR RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME LLC | 2012-05-03 | — | — | US | disclosed |
| US-20100093722-A1 | HETEROARYL AND PHENYL SUBSTITUTED THIENO[2,3-d]PYRIMIDINES AND THEIR USE AS ADENOSINE A2a RECEPTOR ANTAGONISTS | JANSSEN PHARMACEUTICA NV (BE) | 2010-04-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120108595-A1 | PLATELET-ACTIVATING FACTOR RECEPTOR ANTAGONISTS | PTAFR, PAFAH1B2, PAFAH1B3 | SSTR4 2021/4885CACNA1G 3114/4885CACNA1H 3208/4885 |
| US-20100093722-A1 | HETEROARYL AND PHENYL SUBSTITUTED THIENO[2,3-d]PYRIMIDINES AND THEIR USE AS ADENOSINE A2a RECEPTOR ANTAGONISTS | ADORA2A, ADORA3, ADORA2B | SSTR4 1851/4885CACNA1G 2870/4885CACNA1H 2545/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.